Vol. 36 (2021)
Artículos de revisión

The best of the 2020 AHA virtual congress

  • Keril Gianoni,
  • David de Sosa,
  • Macarena Lorente,
  • Sofía Noria,
Keril Gianoni
Centro Cardiovascular Casa de Galicia. Montevideo, Uruguay
David de Sosa
Centro Cardiovascular Universitario, Hospital de Clínicas. Montevideo, Uruguay
Macarena Lorente
Instituto Nacional de Cirugía Cardíaca, Servicio Médico Integral. Montevideo, Uruguay
Sofía Noria
Editora adjunta de la Revista Uruguaya de Cardiología
DOI: https://doi.org/10.29277/cardio.36.1.6
Published 01-04-2021

Keywords:

RIVER, AFFIRM-HF, SCORED, GALACTIC-HF, RHAPSODY, EARLY-FA

Abstract

During the 13th-17th november 2020 period, the anual meeting of the American Heart Association was held. Due to the global pandemic situation that we are going through, it was carried out virtually in its entirety, which allowed a greater participation worldwide. The Guidelines for Cardiopulmonary Resucitation were presented as well as multiple interesting and relevant studies for cardiology, from which we highlight:

- Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve: the RIVER trial.

- Ferric Carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trail: AFFIRM-AHF trial.

- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease: SCORED trial.

- Cardiac Miosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure: the GALACTIC-HF trial.

- Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis: RHAPSODY trial.

- Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation: the EARLY-AF trial.

PDF (Español (España))